Molecular pathology

Latest Association for Molecular Pathology Survey Findings Indicate Significant Decline in Molecular Testing for Cancer During COVID-19 Pandemic

Tuesday, February 23, 2021 - 6:39pm

ROCKVILLE, Md., Feb. 23, 2021 /PRNewswire/ --The Association for Molecular Pathology (AMP), the premier global, molecular diagnostic professional society, today released the preliminary results of its " Molecular Testing for Cancer during COVID-19 " survey of clinical laboratories.

Key Points: 
  • ROCKVILLE, Md., Feb. 23, 2021 /PRNewswire/ --The Association for Molecular Pathology (AMP), the premier global, molecular diagnostic professional society, today released the preliminary results of its " Molecular Testing for Cancer during COVID-19 " survey of clinical laboratories.
  • The latest anonymous survey assessed how important components of molecular diagnostic testing for cancer, including testing volumes, laboratory operations, clinical trial testing, patient samples, and turnaround times, were affected by the COVID-19 pandemic.
  • Overall, 85% of respondents reported that molecular testing for cancer decreased during April-June 2020.
  • The results from this survey underscore the significant supply chain and staffing shortages that were reported in AMP's April and August SARS-CoV-2 molecular testing surveys and show that they reverberate to molecular diagnostic testing for cancer.

NovoPath's AP LIS Receives Frost & Sullivan Technology Leadership Award for its Advanced Features that Transform AP Laboratory Workflow

Tuesday, February 9, 2021 - 1:44pm

The award is based on the company's strong overall performance in enabling laboratories to realize simplified workflows.

Key Points: 
  • The award is based on the company's strong overall performance in enabling laboratories to realize simplified workflows.
  • Additionally, the streamlined operations empower the Anatomic Pathology Lab to provide cost efficiencies, rapid test results and outstanding customer service.
  • By offering a comprehensive Anatomic Pathology Laboratory Information Systems (AP LIS) and by expanding to the molecular pathology and digital pathology laboratory solutions market, NovoPath offers a complete and configurable multidisciplinary platform.
  • "Overall, Frost & Sullivan believes that NovoPath's strategic partnerships with top healthcare service providers, modern technology, and solid brand equity in the AP ecosystem have positioned it as the AP LIS vendor of choice in the North American market.

ProPath Appoints Soft Tissue Tumor Expert, Julia A. Bridge, M.D., as Director of Cytogenetics and FISH

Thursday, January 7, 2021 - 3:07pm

She will also be incorporating her testing expertise in bone/soft tissue tumors for ProPaths molecular pathology team.

Key Points: 
  • She will also be incorporating her testing expertise in bone/soft tissue tumors for ProPaths molecular pathology team.
  • We are thrilled to have Dr. Bridge join our team, said Cory A. Roberts, M.D., President, Chairman and CEO of ProPath.
  • She has a rare combination of expertise in both anatomic pathology and cytogenetics that make her an expert with an international consultative practice.
  • Led by a team of world-class physicians and scientists, ProPath routinely diagnoses cases from 45 states and several foreign countries.

Asuragen to Present at Association for Molecular Pathology (AMP) 2020 Annual Meeting

Tuesday, November 10, 2020 - 1:00pm

Asuragen, Inc., a molecular diagnostics company delivering easy-to-use products for complex testing in genetics and oncology, will host two corporate workshops and present multiple scientific posters highlighting their new and upcoming products at the 2020 Association for Molecular Pathology (AMP) Annual Meeting & Expo, held virtually from November 16-20.

Key Points: 
  • Asuragen, Inc., a molecular diagnostics company delivering easy-to-use products for complex testing in genetics and oncology, will host two corporate workshops and present multiple scientific posters highlighting their new and upcoming products at the 2020 Association for Molecular Pathology (AMP) Annual Meeting & Expo, held virtually from November 16-20.
  • Asuragens corporate workshops will be available on-demand throughout the event and will highlight the newest additions to the companys rapidly growing portfolio.
  • The company will also have a virtual booth during the conference, providing visitors the opportunity to access additional product materials and live chat with Asuragen representatives.
  • Asuragen is a molecular diagnostic product company changing the way patients are treated in genetics and oncology.

Diaceutics Partners With Global EQA Providers to Implement Best-in-class Testing Standards

Monday, September 28, 2020 - 3:10pm

Currently focused on the Canadian market, CPQA-AQCP is dedicated to monitoring and improving the proficiency of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) testing.

Key Points: 
  • Currently focused on the Canadian market, CPQA-AQCP is dedicated to monitoring and improving the proficiency of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) testing.
  • The organization is currently collaborating with Diaceutics on a project sponsoring the HER2 biomarker modules for gastric cancer.
  • UK-based EMQN CIC provides molecular genetics, molecular pathology, and technique-specific EQA schemes for the global molecular testing market.
  • NordiQC actively cooperates with all stakeholders being laboratories, industry and regulatory bodies to promote and establish standards for immunohistochemical precision testing.

PathGroup Selected by NIH to Become RADx Program “Mega-Lab” for COVID-19 Testing

Wednesday, September 2, 2020 - 6:04pm

The RADxSM initiative supports the development, production scale-up, and deployment of accurate, rapid SARS-CoV-2 tests across the country.

Key Points: 
  • The RADxSM initiative supports the development, production scale-up, and deployment of accurate, rapid SARS-CoV-2 tests across the country.
  • PathGroup is proud to be selected by the NIH RADxSM initiative to expand our industry-leading testing with 24-hour turnaround times, bringing ultra-high throughput testing capacity from some of the worlds leading diagnostic manufacturers to our clinician partners and the patients we collectively serve.
  • Nashville-based PathGroup provides comprehensive COVID-19 testing services for hospitals, physician offices, state and local departments of health, employers, and school systems, including both molecular diagnostic and antibody testing.
  • Founded in 1965, PathGroup is a premier provider of anatomic, clinical and molecular pathology laboratory services in the United States.

Avero Diagnostics Expands COVID-19 Testing Capabilities with Launch of Serology Testing

Tuesday, August 25, 2020 - 10:30am

Avero Diagnostics , a physician-owned laboratory, is pleased to announce the expansion of its COVID-19 testing portfolio with the addition of the Roche Elecsys Anti-SARS-CoV-2 antibody test.

Key Points: 
  • Avero Diagnostics , a physician-owned laboratory, is pleased to announce the expansion of its COVID-19 testing portfolio with the addition of the Roche Elecsys Anti-SARS-CoV-2 antibody test.
  • As the medical and scientific communities work to understand and stop the spread of COVID-19, serological testing serves as a piece of the very complex puzzle, said Trae Mattison, MD, Managing Partner, Avero Diagnostics.
  • Avero Diagnostics CLIA-certified and CAP-accredited laboratory is using the Roche immunoassay for the qualitative detection of antibodies against SARS-CoV-2.
  • Avero Diagnostics vision is to lead the healthcare industry in the delivery of anatomic pathology, molecular pathology and genetic testing.

Acupath Launches COVID19 Testing in NY and Beyond

Friday, May 29, 2020 - 2:00pm

PLAINVIEW, N.Y., May 29, 2020 /PRNewswire/ -- Acupath Laboratories, Inc., a leading provider of sub-specialized anatomic and molecular pathology services, announces the launch of COVID-19 testing utilizing the FDA EUA approved ThermoFisher TaqPath RT-PCR COVID-19 Combo kit.

Key Points: 
  • PLAINVIEW, N.Y., May 29, 2020 /PRNewswire/ -- Acupath Laboratories, Inc., a leading provider of sub-specialized anatomic and molecular pathology services, announces the launch of COVID-19 testing utilizing the FDA EUA approved ThermoFisher TaqPath RT-PCR COVID-19 Combo kit.
  • With results available within 24 48 hours, Acupath's test is highly sensitive, as it is one of the few labs targeting regions of three coronavirus genes; orf-1ab, S protein, and N protein, as well as MS2 phage control.
  • "Thanks to the hard work of our team, we are now able to do our part and expand testing capabilities in the greater New York City area and beyond to help the region and country reopen," said Steve Kamalic, Chief Operating Officer.
  • Founded in 1998 and based in Plainview, NY (Long Island), Acupath is a provider of sub-specialized anatomic pathology services focused on the following specialties; Urology, Gastroenterology, Dermatology, Women's Health, Otolaryngology, Podiatry, and Hematology / Oncology.

Avero Diagnostics Now Offering COVID-19 Testing

Tuesday, May 19, 2020 - 5:55pm

Avero Diagnostics , a physician-owned laboratory, is now providing molecular testing for COVID-19.

Key Points: 
  • Avero Diagnostics , a physician-owned laboratory, is now providing molecular testing for COVID-19.
  • For the protection of our community, its imperative that testing be made available to people who are symptomatic or have been exposed to someone with COVID-19, said Trae Mattison, MD, Managing Partner, Avero Diagnostics.
  • Avero Diagnostics is working to coordinate with regional officials to ensure our lab is added to the official testing capacity for the region, support the demands of the local healthcare community, and help alleviate the current testing shortfall.
  • Avero Diagnostics vision is to lead the healthcare industry in the delivery of anatomic pathology, molecular pathology and genetic testing.

Largest North American Site for FSHD Muscular Dystrophy Testing Adopts Bionano Genomics’ Saphyr for Majority of Clinical Tests 

Wednesday, April 22, 2020 - 1:00pm

The UIHC recently completed development of an FSHD assay on Saphyr and validated its results by processing patient samples for FSHD.

Key Points: 
  • The UIHC recently completed development of an FSHD assay on Saphyr and validated its results by processing patient samples for FSHD.
  • Following this evaluation, the UIHC is implementing this month a Saphyr-based assay into its clinical testing workflow.
  • One component of genetically confirming a diagnosis of FSHD is measuring the exact number of D4Z4 repeats.
  • The Molecular Pathology Laboratory at the University of Iowa, directed by Aaron Bossler MD, PhD, is the largest FSHD testing site in North America and to date has relied on the labor-intensive technique of Southern blotting for FSHD molecular diagnostic testing.